# Frontier Medicines Corporation

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/frontier-medicines

- Industry: Biotechnology
- Headquarters: South San Francisco, US
- Website: www.frontiermeds.com
- Total disclosed funding: $256M
- Latest round: Series C (Jun 25, 2024)
- Investors on record: 11

## About

Based in California, US, and founded in 2018 by CEO Chris Varma and Daniel Nomura, Frontier Medicines Corporation operates as a biopharmaceutical company that utilizes chemoproteomics to discover and develop therapies that target the binding pockets on proteins and enable them to be accessible for therapeutic intervention. In June 2024, Frontier Medicines Corporation raised USD 20 million in Series C funding from ArrowMark Partners, and Deep Track Capital.. The round was part of a larger USD 100 million series C funding.

Frontier Medicines focuses on developing precision-based treatments with an initial emphasis on oncology. The company’s primary product is a dual KRASG12C inhibitor, designed to target both active and inactive forms of the KRAS mutation. The firm’s approach integrates advanced scientific techniques, including chemoproteomics and machine learning, to build a precision pipeline of medicines. This pipeline aims to address specific cancer-related mutations, improving treatment efficacy and patient outcomes. Frontier Medicines operates from offices in South San Francisco and Boston, supporting their research and development efforts.

The company plans to use its proceeds from June 2024 funding to support its clinical research advancement.

## Funding rounds

- Series C, Jun 25, 2024, $20M — ArrowMark Partners, Deep Track Capital
- Series C, Feb 22, 2024, $80M — MPM BioImpact, Galapagos NV, DCVC, Deerfield Management, RA Capital Management, Droia Ventures
- Series B, Jun 25, 2021, $89M — MPM BioImpact, ArrowMark Partners, Driehaus Capital Management, DCVC, Deerfield Management, RA Capital Management, Sphera Funds Management, Droia Ventures, Woodline Partners, Deep Track Capital
- Series A, Nov 2, 2020, $34M — MPM BioImpact, DCVC, Deerfield Management, RA Capital Management, Droia Ventures
- Series A, Jun 25, 2019, $34M — MPM BioImpact, DCVC, Deerfield Management, RA Capital Management, Droia Ventures

## Investors

- MPM BioImpact (https://capitalatlas.ai/funds/mpm-bioimpact) — Series A, Series B, Series C
- DCVC (https://capitalatlas.ai/funds/dcvc) — Series A, Series B, Series C
- Deerfield Management (https://capitalatlas.ai/funds/deerfield-management) — Series A, Series B, Series C
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series A, Series B, Series C
- Droia Ventures (https://capitalatlas.ai/funds/droia-ventures) — Series A, Series B, Series C
- ArrowMark Partners — Series B, Series C
- Driehaus Capital Management (https://capitalatlas.ai/funds/driehaus-capital-management) — Series B
- Sphera Funds Management — Series B
- Woodline Partners — Series B
- Deep Track Capital (https://capitalatlas.ai/funds/deep-track-capital) — Series B, Series C
- Galapagos NV — Series C